Clinical presentation and management of moxidectin toxicity in two dogs.
Moxidectin is a macrocyclic lactone related to ivermectin used in horses and dogs for endoparasite treatment and prophylaxis. The clinical and neurological presentation of moxidectin toxicity in two dogs following inadvertent poisoning with a moxidectin-containing equine de-worming medication is reported here. In both the dogs, the predominant clinical signs were generalised tremors and ataxia. Moxidectin exerts its neurotoxic effects in mammals by potentiating the effect of gamma-aminobutyric acid and, consistent with this, both the dogs demonstrated a poor response to treatment with diazepam. It would be more appropriate to avoid gamma-aminobutyric acid agonists, such as benzodiazepines and barbiturates, in dogs with moxidectin toxicity and consider using anaesthetic agents with a different mode of action, such as propofol. The prognosis in dogs accidentally exposed to moxidectin-containing equine de-worming medication appears to be excellent if the cause of the neurotoxicity is correctly identified and the case is appropriately managed.
Snowden
N J
NJ
Animal Health Trust, Lanwades Park, Kentford, Newmarket CB8 7UU.
Helyar
C V
CV
Platt
S R
SR
Penderis
J
J
D000818:Animals; D000871:Anthelmintics / Q000506:poisoning*; D001259:Ataxia / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary; D003937:Diagnosis, Differential; D004283:Dog Diseases / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D004285:Dogs; D005260:Female; D006993:Hypnotics and Sedatives / Q000627:therapeutic use*; D018942:Macrolides / Q000506:poisoning; D008297:Male; D011379:Prognosis; D015742:Propofol / Q000627:therapeutic use*; D016896:Treatment Outcome
D000871:Anthelmintics; D006993:Hypnotics and Sedatives; D018942:Macrolides; C027837:moxidectin; D015742:Propofol